Piper Jaffray Companies Weighs in on Proteostasis Therapeutics Inc’s Q3 2018 Earnings (PTI)

Proteostasis Therapeutics Inc (NASDAQ:PTI) – Equities researchers at Piper Jaffray Companies issued their Q3 2018 earnings estimates for Proteostasis Therapeutics in a research report issued to clients and investors on Monday, October 29th, according to Zacks Investment Research. Piper Jaffray Companies analyst E. Tenthoff forecasts that the company will post earnings of ($0.47) per share for the quarter. Piper Jaffray Companies currently has a “Overweight” rating and a $14.00 target price on the stock. Piper Jaffray Companies also issued estimates for Proteostasis Therapeutics’ Q4 2018 earnings at ($0.40) EPS, FY2018 earnings at ($1.60) EPS, Q1 2019 earnings at ($0.49) EPS, Q2 2019 earnings at ($0.55) EPS, Q3 2019 earnings at ($0.55) EPS, Q4 2019 earnings at ($0.61) EPS and FY2019 earnings at ($2.20) EPS.

Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Proteostasis Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 price objective for the company in a research report on Tuesday, October 23rd. Cantor Fitzgerald began coverage on shares of Proteostasis Therapeutics in a research report on Tuesday, November 6th. They issued a “buy” rating and a $21.00 price objective for the company. ValuEngine raised shares of Proteostasis Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Proteostasis Therapeutics in a research report on Thursday, October 18th. Finally, Royal Bank of Canada raised shares of Proteostasis Therapeutics from a “sector perform” rating to an “outperform” rating in a research report on Thursday, October 18th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. Proteostasis Therapeutics presently has a consensus rating of “Buy” and an average target price of $13.86.

Shares of NASDAQ:PTI traded down $0.10 during trading on Wednesday, reaching $5.59. The stock had a trading volume of 1,113,662 shares, compared to its average volume of 2,220,073. Proteostasis Therapeutics has a one year low of $1.71 and a one year high of $10.38. The stock has a market capitalization of $208.81 million, a P/E ratio of -2.39 and a beta of -3.25.

In related news, Director Franklin M. Berger acquired 40,000 shares of the firm’s stock in a transaction that occurred on Friday, October 26th. The stock was purchased at an average cost of $6.75 per share, with a total value of $270,000.00. Following the transaction, the director now directly owns 266,162 shares of the company’s stock, valued at approximately $1,796,593.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 19.80% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Baird Financial Group Inc. purchased a new position in Proteostasis Therapeutics during the 3rd quarter worth approximately $213,000. Jennison Associates LLC raised its position in Proteostasis Therapeutics by 0.7% during the 3rd quarter. Jennison Associates LLC now owns 3,690,138 shares of the company’s stock worth $8,893,000 after buying an additional 26,428 shares during the last quarter. Northern Trust Corp raised its position in Proteostasis Therapeutics by 526.1% during the 2nd quarter. Northern Trust Corp now owns 269,451 shares of the company’s stock worth $752,000 after buying an additional 226,417 shares during the last quarter. Bank of New York Mellon Corp raised its position in Proteostasis Therapeutics by 252.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,319 shares of the company’s stock worth $174,000 after buying an additional 44,653 shares during the last quarter. Finally, BlackRock Inc. raised its position in Proteostasis Therapeutics by 3,693.4% during the 2nd quarter. BlackRock Inc. now owns 1,807,717 shares of the company’s stock worth $5,043,000 after buying an additional 1,760,063 shares during the last quarter. 64.84% of the stock is owned by institutional investors.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study.

Read More: Moving Average (MA)

Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply